Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs

키워드

참고문헌 (116)

1. 진동찬, "Analysis of mortality risk from Korean hemodialysis registry data 2017", Kidney Research and Clinical Practice, 38(2), pp.169~175 (2019), 대한신장학회[DOI]
2. Choi HS, "Trends in the incidence and prevalence of end-stage renal disease with hemodialysis in entire Korean population: a nationwide population-based study", Medicine(Baltimore), 100, pp.e25293~ (2021)
3. Lundy DS, "Aspiration : cause and implications", Otolaryngol Head Neck Surg, 120, pp.474~478 (1999)
4. Su Woong Jung, "The role of inflammation in diabetic kidney disease", The Korean Journal of Internal Medicine, 36(4), pp.753~766 (2021), 대한내과학회[DOI]
5. Ye Seul Yang, "Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need", The Korean Journal of Internal Medicine, 36(5), pp.1049~1058 (2021), 대한내과학회[DOI]
6. Kipyo Kim, "Current findings of kidney biopsy including nephropathy associated with hypertension and diabetes mellitus in Korea", The Korean Journal of Internal Medicine, 35(5), pp.1173~1187 (2020), 대한내과학회[DOI]
7. Kumar S, "Why do young people with chronic kidney disease die early?", World J Nephrol, 3, pp.143~155 (2014)
8. 김경민, "Impact of chronic kidney disease on mortality: A nationwide cohort study", Kidney Research and Clinical Practice, 38(3), pp.382~390 (2019), 대한신장학회[DOI]
9. 김미경, "Treatment of diabetic kidney disease: current and future targets", The Korean Journal of Internal Medicine, 32(4), pp.622~630 (2017), 대한내과학회[DOI]
10. 김예니, "New therapeutic agents in diabetic nephropathy", The Korean Journal of Internal Medicine, 32(1), pp.11~25 (2017), 대한내과학회[DOI]
11. 고승현, "Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association", The Korean Journal of Internal Medicine, 32(6), pp.947~958 (2017), 대한내과학회[DOI]
12. Kim Kipyo, "Effect of estimating equations for glomerular filtration rate on novel surrogate markers for renal outcome", Kidney Research and Clinical Practice, 40(2), pp.220~230 (2021), 대한신장학회[DOI]
13. Kidney Disease : Improving Global Outcomes(KDIGO)Diabetes Work Group, "KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease", Kidney Int, 98, pp.S1~ (2020)[DOI]
14. Afkarian M, "Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014", JAMA, 316, pp.602~610 (2016)
15. Pugliese G, "Updating the natural history of diabetic nephropathy", Acta Diabetol, 51, pp.905~915 (2014)
16. Gregg EW, "Changes in diabetes-related complications in the United States, 1990-2010", N Engl J Med, 370, pp.1514~1523 (2014)
17. 이민정, "Trends in the Incidence, Prevalence, and Mortality of End-Stage Kidney Disease in South Korea", Diabetes and Metabolism Journal, 44(6), pp.933~937 (2020), 대한당뇨병학회[DOI]
18. Retnakaran R, "Risk factors for renal dysfunction in type 2 diabetes : U. K. Prospective Diabetes Study 74", Diabetes, 55, pp.1832~1839 (2006)
19. Zoppini G, "Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function", Clin J Am Soc Nephrol, 7, pp.401~408 (2012)
20. Jiang G, "Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes", Kidney Int, 95, pp.178~187 (2019)
21. Packham DK, "Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2diabetes and nephropathy : results from the DIAMETRIC(Diabetes Mellitus Treatment for Renal Insufficiency Consortium)database", Am J Kidney Dis, 59, pp.75~83 (2012)
22. Kussman MJ, "The clinical course of diabetic nephropathy", JAMA, 236, pp.1861~1863 (1976)
23. Mogensen CE, "The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy", Diabetes, 32(Suppl 2), pp.64~78 (1983)
24. Skupien J, "Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes", Diabetes Care, 39, pp.2262~2269 (2016)
25. Molitch ME, "Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study", Diabetes Care, 33, pp.1536~1543 (2010)
26. Krolewski AS, "Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria", Diabetes Care, 37, pp.226~234 (2014)
27. Vistisen D, "Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria", Diabetes Care, 42, pp.1886~1894 (2019)
28. Wetzels JF, "Age-and gender-specific reference values of estimated GFR in Caucasians : the Nijmegen Biomedical Study", Kidney Int, 72, pp.632~637 (2007)
29. American Diabetes Association, "11. Microvascular complications and foot care : standards of medical care in diabetes-2021", Diabetes Care, 44(Suppl 1), pp.S151~S167 (2021)
30. Caramori ML, "Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients : an indicator of more advanced glomerular lesions", Diabetes, 52, pp.1036~1040 (2003)
31. Nistor I, "Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice", Nephrol Dial Transplant, 32, pp.1268~1273 (2017)
32. Prischl FC, "Renal outcomes of antidiabetic treatment options for type 2 diabetes : a proposed MARE definition", Kidney Int Rep, 3, pp.1030~1038 (2018)
33. Tong A, "Composing a new song for trials : the Standardized Outcomes in Nephrology(SONG)initiative", Nephrol Dial Transplant, 32, pp.1963~1966 (2017)
34. Stevens LA, "Surrogate end points for clinical trials of kidney disease progression", Clin J Am Soc Nephrol, 1, pp.874~884 (2006)
35. Heerspink HJL, "Change in albuminuria as a surrogate endpoint for progression of kidney disease : a meta-analysis of treatment effects in randomised clinical trials", Lancet Diabetes Endocrinol, 7, pp.128~139 (2019)
36. Looker HC, "Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes", J Am Soc Nephrol, 30, pp.1049~1059 (2019)
37. Heerspink HJ, "Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis", J Am Soc Nephrol, 26, pp.2055~2064 (2015)
38. Mulder S, "An integrative systems biology approach for precision medicine in diabetic kidney disease", Diabetes Obes Metab, 20(Suppl 3), pp.6~13 (2018)
39. Breyer JA, "Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group", Kidney Int, 50, pp.1651~1658 (1996)
40. Hunsicker LG, "Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study", Kidney Int, 51, pp.1908~1919 (1997)
41. Fattah H, "How do kidneys adapt to a deficit or loss in nephron number?", Physiology (Bethesda), 34, pp.189~197 (2019)
42. Levey AS, "Measured and estimated glomerular filtration rate : current status and future directions", Nat Rev Nephrol, 16, pp.51~64 (2020)
43. Lee E, "Interlaboratory variability in plasma creatinine measurement and the relation with estimated glomerular filtration rate and chronic kidney disease diagnosis", Clin J Am Soc Nephrol, 12, pp.29~37 (2017)
44. Grams ME, "Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials : an individual participant meta-analysis of observational data", J Am Soc Nephrol, 30, pp.1746~1755 (2019)
45. Greene T, "A model for a proportional treatment effect on disease progression", Biometrics, 57, pp.354~360 (2001)
46. Yamada Y, "The mode of action of caffeine on catecholamine release from perfused adrenal glands of cat", Br J Pharmacol, 98, pp.351~356 (1989)
47. Kraus BJ, "Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial", Kidney Int, 99, pp.750~762 (2021)
48. Wright JT Jr, "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial", JAMA, 288, pp.2421~2431 (2002)
49. Klahr S, "The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group", N Engl J Med, 330, pp.877~884 (1994)
50. Barnett AH, "Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy", N Engl J Med, 351, pp.1952~1961 (2004)
51. Li L, "Longitudinal progression trajectory of GFR among patients with CKD", Am J Kidney Dis, 59, pp.504~512 (2012)
52. Ambrogi V, "Patterns and predictors of kidney function decline in the last year prior to dialysis", Nephron Clin Pract, 111, pp.c95~c101 (2009)
53. Weldegiorgis M, "Longitudinal estimated GFR trajectories in patients with and without type 2diabetes and nephropathy", Am J Kidney Dis, 71, pp.91~101 (2018)
54. Greene T, "Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials : a statistical simulation", J Am Soc Nephrol, 30, pp.1756~1769 (2019)
55. Kyu Yeon Hur, "Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement", Kidney Research and Clinical Practice, 39(1), pp.32~39 (2020), 대한신장학회[DOI]
56. de Boer IH, "Executive summary of the 2020 KDIGO diabetes management in CKD guideline : evidence-based advances in monitoring and treatment", Kidney Int, 98, pp.839~848 (2020)
57. Wanner C, "Empagliflozin and progression of kidney disease in type 2 diabetes", N Engl J Med, 375, pp.323~334 (2016)
58. Cherney DZI, "Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease : an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial", Lancet Diabetes Endocrinol, 5, pp.610~621 (2017)
59. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
60. Perkovic V, "Canagliflozin and renal outcomes in type 2 diabetes : results from the CANVAS Program randomised clinical trials", Lancet Diabetes Endocrinol, 6, pp.691~704 (2018)
61. Neuen BL, "Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria : data from the CANVAS program", J Am Soc Nephrol, 30, pp.2229~2242 (2019)
62. Mosenzon O, "Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes : an analysis from the DECLARE-TIMI 58 randomised trial", Lancet Diabetes Endocrinol, 7, pp.606~617 (2019)
63. Neuen BL, "SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes : a systematic review and meta-analysis", Lancet Diabetes Endocrinol, 7, pp.845~854 (2019)
64. Heerspink HJL, "Dapagliflozin in patients with chronic kidney disease", N Engl J Med, 383, pp.1436~1446 (2020)
65. Oshima M, "Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice", Kidney Int, 99, pp.999~1009 (2021)
66. Heerspink H, "Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation", Clin J Am Soc Nephrol, 16, pp.1278~1280 (2021)
67. 오태정, "Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement", Kidney Research and Clinical Practice, 39(3), pp.269~286 (2020), 대한신장학회[DOI]
68. Heerspink H, "Renoprotective effects of sodium-glucose cotransporter-2 inhibitors", Kidney Int, 94, pp.26~39 (2018)
69. DeFronzo RA, "Pathophysiology of diabetic kidney disease : impact of SGLT2 inhibitors", Nat Rev Nephrol, 17, pp.319~334 (2021)
70. Brenner BM, "Hemodynamically mediated glomerular injury and the progressive nature of kidney disease", Kidney Int, 23, pp.647~655 (1983)
71. Thomson SC, "Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis", J Am Soc Nephrol, 19, pp.2272~2275 (2008)
72. Vallon V, "Renal function in diabetic disease models : the tubular system in the pathophysiology of the diabetic kidney", Annu Rev Physiol, 74, pp.351~375 (2012)
73. Rigalleau V, "Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease", BMC Nephrol, 11, pp.3~ (2010)
74. van Bommel E, "The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial", Kidney Int, 97, pp.202~212 (2020)
75. Cherney DZ, "Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes", Kidney Int, 86, pp.1057~1058 (2014)
76. Groop PH, "Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes : post-hoc renal analysis of the DEPICT randomised controlled trials", Lancet Diabetes Endocrinol, 8, pp.845~854 (2020)
77. Ghanim H, "Dapagliflozin suppresses hepcidin and increases erythropoiesis", J Clin Endocrinol Metab, 105, pp.dgaa057~ (2020)
78. DeFronzo RA, "Renal, metabolic and cardiovascular considerations of SGLT2 inhibition", Nat Rev Nephrol, 13, pp.11~26 (2017)
79. Ferrannini E, "Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients", J Clin Invest, 124, pp.499~508 (2014)
80. Heerspink HJL, "Canagliflozin reduces inflammation and fibrosis biomarkers : a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease", Diabetologia, 62, pp.1154~1166 (2019)
81. Brown E, "SGLT2 inhibitors and GLP-1 receptor agonists : established and emerging indications", Lancet, 398, pp.262~276 (2021)
82. Gentilella R, "Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment : are they all the same", Diabetes Metab Res Rev, 35, pp.e3070~ (2019)
83. Mann J, "Liraglutide and renal outcomes in type 2 diabetes", N Engl J Med, 377, pp.839~848 (2017)
84. Gerstein HC, "Dulaglutide and renal outcomes in type 2 diabetes : an exploratory analysis of the REWIND randomised, placebo-controlled trial", Lancet, 394, pp.131~138 (2019)
85. Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes", N Engl J Med, 375, pp.1834~1844 (2016)
86. Mann J, "Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes : a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials", Lancet Diabetes Endocrinol, 8, pp.880~893 (2020)
87. Holman RR, "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 377, pp.1228~1239 (2017)
88. van der Aart-van der Beek AB, "Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk : a post hoc analysis of the EXSCEL trial", Diabetes Obes Metab, 22, pp.2493~2498 (2020)
89. Tuttle KR, "Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease(AWARD-7) : a multicentre, open-label, randomised trial", Lancet Diabetes Endocrinol, 6, pp.605~617 (2018)
90. Muskiet M, "GLP-1 and the kidney : from physiology to pharmacology and outcomes in diabetes", Nat Rev Nephrol, 13, pp.605~628 (2017)
91. Gutzwiller JP, "Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men", J Clin Endocrinol Metab, 89, pp.3055~3061 (2004)
92. Tonneijck L, "Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes : a 12-week, randomized, double-blind, placebo-controlled trial", Diabetes Care, 39, pp.2042~2050 (2016)
93. Tonneijck L, "Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine : an 8-week, randomised, open-label trial", Diabetes Obes Metab, 19, pp.1669~1680 (2017)
94. Thomson SC, "Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat", Am J Physiol Renal Physiol, 304, pp.F137~F144 (2013)
95. Thomson SC, "Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorption", J Clin Invest, 104, pp.1149~1158 (1999)
96. Rieg T, "Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice", Am J Physiol Renal Physiol, 303, pp.F963~F971 (2012)
97. von Scholten BJ, "Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment", Diabet Med, 32, pp.343~352 (2015)
98. von Scholten BJ, "The effect of liraglutide on renal function : a randomized clinical trial", Diabetes Obes Metab, 19, pp.239~247 (2017)
99. Fujita H, "The protective roles of GLP-1R signaling in diabetic nephropathy : possible mechanism and therapeutic potential", Kidney Int, 85, pp.579~589 (2014)
100. Tanaka T, "The potential for renoprotection with incretin-based drugs", Kidney Int, 86, pp.701~711 (2014)
101. Park CW, "Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db", db mice, 2007, pp.18, 1227~1238
102. Bunck MC, "Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition", Diabetes Care, 33, pp.1734~1737 (2010)
103. Rizzo M, "Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes : a prospective pilot study", J Clin Endocrinol Metab, 100, pp.603~606 (2015)
104. Zhang H, "Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria", Kidney Blood Press Res, 35, pp.483~488 (2012)
105. Williams DM, "Renal outcomes in type 2diabetes : a review of cardiovascular and renal outcome trials", Diabetes Ther, 11, pp.369~386 (2020)
106. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
107. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
108. Mosenzon O, "Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial", Diabetes Care, 40, pp.69~76 (2017)
109. Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)
110. Cornel JH, "Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes : outcomes from TECOS", Diabetes Care, 39, pp.2304~2310 (2016)
111. Rosenstock J, "Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk : the CARMELINA randomized clinical trial", JAMA, 321, pp.69~79 (2019)
112. 배재현, "Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis", Endocrinology and Metabolism, 34(1), pp.80~92 (2019), 대한내분비학회[DOI]
113. Kanasaki K, "The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin", Clin Sci(Lond), 132, pp.489~507 (2018)
114. Lovshin JA, "Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α1-67 in patients with type 2 diabetes", Diabetes Care, 40, pp.1073~1081 (2017)
115. Zhou X, "Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats", Cardiovasc Diabetol, 14, pp.29~ (2015)
116. Takashima S, "Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy", Kidney Int, 90, pp.783~796 (2016)

관련 논문AI추천